Oruka Therapeutics (NASDAQ:ORKA) Shares Climb 11.2% – What’s Next?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) shares were up 11.2% during trading on Monday. The stock traded as high as $88.68 and last traded at $89.1520. 133,034 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 1,077,736 shares. The stock had previously closed at $80.15.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ORKA shares. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. HC Wainwright restated a “buy” rating and set a $120.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, September 24th. Piper Sandler reaffirmed an “overweight” rating on shares of Oruka Therapeutics in a report on Wednesday, October 7th. BTIG Research reiterated a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a research note on Monday, October 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Oruka Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $128.91.

Oruka Therapeutics Stock Up 14.6%

The firm’s 50 day moving average is $89.62 and its two-hundred day moving average is $81.20. The stock has a market cap of $6.08 billion, a price-to-earnings ratio of -45.33 and a beta of -0.37.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Arjun Agarwal sold 9,999 shares of the business’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $80.60, for a total transaction of $805,919.40. Following the completion of the transaction, the senior vice president owned 14,219 shares in the company, valued at $1,146,051.40. The trade was a 41.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $74.81, for a total value of $523,670.00. Following the transaction, the insider owned 31,771 shares of the company’s stock, valued at approximately $2,376,788.51. The trade was a 18.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 154,950 shares of company stock valued at $14,102,680. Insiders own 23.49% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Algert Global LLC increased its stake in shares of Oruka Therapeutics by 3.5% in the second quarter. Algert Global LLC now owns 5,380 shares of the company’s stock valued at $512,000 after purchasing an additional 180 shares during the period. GAMMA Investing LLC raised its holdings in shares of Oruka Therapeutics by 201.6% during the third quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock valued at $31,000 after buying an additional 250 shares during the last quarter. Nykredit A S bought a new stake in shares of Oruka Therapeutics during the second quarter valued at approximately $29,000. AlphaCentric Advisors LLC boosted its position in shares of Oruka Therapeutics by 5.8% during the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock worth $564,000 after buying an additional 626 shares during the period. Finally, Orion Capital Management LLC acquired a new position in shares of Oruka Therapeutics during the second quarter worth approximately $91,000. 56.44% of the stock is currently owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.